About this trial
In order to provide treatment in pediatric hematology-oncology patients, in some cases a central venous catheter is required in children. The most important situation to pay attention to when using a central venous catheter is "Central line-associated bloodstream infections".
These infections are infections that develop after admission to the hospital and are not in the incubation period at the time of admission, or although they usually develop in the hospital 48-72 hours after hospitalization, they can sometimes appear after discharge. Central line-associated bloodstream infections significantly increase morbidity and mortality. In this context, the effect of using a care bundle containing chlorhexidine dressing on port catheter and central venous catheter-related bloodstream infections in pediatric cancer patients was examined.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The child is receiving inpatient treatment at the Hematology and Oncology unit and hematopoietic stem cell transplantation unit
The child has a diagnosis of hematological or oncological cancer
The child's age range is between 1 and 17
Having a port catheter inserted and no early complications have occurred
Disqualifiers
Have a systemic infection.
Trial design
Parallel
Treatments tested in this trial
Chlorhexidine Dressing
DeviceTransparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
Treatment groups
Trial outcomes
Primary outcomes
Central line-associated bloodstream infections
defined as the recovery of a pathogen from a blood culture in a patient who had a central line at the time of infection or within 48 hours before the development of infection
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Dokuz Eylul University
Lead sponsor
Afyonkarahisar Health Science University
Collaborator